Ian Tomlinson
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (31)
Background: Over 20 susceptibility single-nucleotide polymorphisms (SNP) have been identified for esophageal adenocarcinoma (EAC) and its precursor, Barrett esophagus (BE), explaining a small portion of heritability. Methods: Using genetic data from 4,323 BE and 4,116 EAC patients aggregated by international consortia including the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), we conducted a comprehensive transcriptome-wide association study (TWAS) for BE/EAC, leveraging Genotype Tissue Expression (GTEx) gene-expression data from six tissue types of plausible relevance to EAC etiology: mucosa and muscularis from the esophagus, gastroesophageal (GE) junction, stomach, whole blood, and visceral adipose. Two analytical approaches were taken: standard TWAS using the predicted gene expression from local expression quantitative trait loci (eQTL), and set-based SKAT association using selected eQTLs that predict the gene expression. Results: Although the standard approach did not identify significant signals, the eQTL set–based approach identified eight novel associations, three of which were validated in independent external data (eQTL SNP sets for EXOC3 , ZNF641 , and HSP90AA1 ). Conclusions: This study identified novel genetic susceptibility loci for EAC and BE using an eQTL set–based genetic association approach. Impact: This study expanded the pool of genetic susceptibility loci for EAC and BE, suggesting the potential of the eQTL set–based genetic association approach as an alternative method for TWAS analysis.
Year:
2025
Classes of BRAF mutation exhibit distinct clinicopathologic and molecular characteristics. A, Subdivision of the large bowel into the proximal and distal colorectum. Proportions of colorectal cancers in each location are shown by BRAF mutation class. B, CMS classifications of BRAF -mutant colorectal cancers by mutation class. The differences between class 2 or 3 versus class 1 (V600E) were highly significant ( P P = 0.270). C and D, Sanger sequencing chromatograms highlighting the spatial co-occurrence of BRAF and additional Ras pathway mutations in two colorectal cancers. Two regions of each cancer were microdissected, DNA was extracted, and relevant exons were PCR-amplified prior to Sanger sequencing. Illustrative results are shown. The co-occurrence of BRAF G466V and NRAS G12D can be observed in tumor 1 ( C ), and of BRAF D594G and KRAS L19F in tumor 2 ( D ). This analysis does not exclude fine-scale spatial mixing of distinct subclones but is consistent with the two mutations tested being present in the same tumor cells. (Created with BioRender.com .)
Year:
2025
Supplementary Figure 4. Kaplan-Meier survival curves of unadjusted overall survival (OS, months) for CRCs harboring a Class 1, 2, or 3 BRAF mutation. A: Overall survival by BRAF class irrespective of additional Ras status. B: Class 1, 2, and 3 in the absence of additional Ras. C: Class 1 and 3 absent additional Ras, and class 3 with additional Ras. Survival as shown is not corrected for covariates, whereas mixed-effects models including several covariates are reported in the main text and Table 2. Class 2 samples with survival data containing additional Ras status were insufficient for this analysis, as discussed in the main text.
Year:
2025
Supplementary Figure 3. Molecular subtyping of BRAF-mutant CRCs into the consensus molecular subtypes of CRC (CMS). Left: CMS groupings within BRAF classes 1 to 3. Right: CMS groups when stratified with the A-B-C positional classifier.
Year:
2025
mRNA expression of the EGFR ligands AREG and EREG . A, Expression of AREG and EREG is significantly increased in the distal colorectum vs. proximal colon across the INTERMPHEN ( n = 119 proximal and n = 236 distal colorectum) and TCGA COADREAD ( n = 18 proximal and n = 19 distal/rectal). Log 2 FC and significance values obtained via DESeq2 analysis (see Materials and Methods). B, Expression of EREG is significantly increased in class 3 BRAF -mutant colorectal cancers vs. class 1 in the absence of a concomitant Ras mutation ( P .adj BioRender.com .)
Year:
2025
BRAF mutations in colorectal cancer comprise three functional classes: class 1 (V600E) with strong constitutive activation, class 2 with pathogenic kinase activity lower than that of class 1, and class 3 which paradoxically lacks kinase activity. Non–class 1 mutations associate with better prognosis, microsatellite stability, distal tumor location, and better anti-EGFR response. An analysis of 13 colorectal cancer cohorts ( n = 6,605 tumors) compared class 1 ( n = 709, 10.7% of colorectal cancers), class 2 ( n = 31, 0.47%), and class 3 ( n = 81, 1.22%) mutations. Class 2–mutant and class 3–mutant colorectal cancers frequently co-occurred with additional Ras pathway mutations (29.0% and 45.7%, respectively, vs. 2.40% in class 1; P KRAS noncodon 12/13/61, NRAS , or NF1 ). Ras pathway activation was highest in class 1 and lowest in class 3, with a greater distal expression of EGFR ligands (amphiregulin/epiregulin) supporting weaker BRAF driver mutations. Unlike class 1 mutants, class 3 tumors resembled chromosomally unstable colorectal cancers in mutation burdens, signatures, driver mutations, and transcriptional subtypes, whereas class 2 mutants displayed intermediate characteristics. Atypical BRAF mutations were associated with longer overall survival than class 1 mutations (HR = 0.25; P = 0.011) but lost this advantage in cancers with additional Ras mutations (HR = 0.94; P = 0.86). This study supports the suggestion that class 3 BRAF mutations amplify existing Ras signaling in a two-mutation model and that the enhancement of weak/atypical Ras mutations may suffice for tumorigenesis, with potentially clinically important heterogeneity in the class 2/3 subgroup. Implications: The heterogeneous nature of BRAF -mutant colorectal cancers, particularly among class 2/3 mutations which frequently harbor additional Ras mutations, highlights the necessity of comprehensive molecular profiling.
Year:
2025
Supplementary Table 7. Logistic regression models of CMS groups by BRAF mutation class, with covariates: tumour location (left or right colon), MSI status, age, sex, and additional Ras status (Class 1/2/3 left, A-B-C right).
Year:
2025
Supplementary Table 4. Summary data reclassified using a positional based system based on proximity to functional domains, which may hold value in exploring atypical BRAF variants not yet functionally assessed (Classes A, B, and C). A single instance of co-occurring class 2 and 3 BRAF is omitted from the total counts yet presented as MSS with no additional clinical data available.
Year:
2025
Supplementary Figure 2. Scaled Schoenfeld residuals for corresponding fixed-effect models, inclusive of study as a categorical variable, relating to mixed-effects survival models in Table 2. A. Model I compares BRAF classes across all patients irrespective of additional Ras mutation; B. Model II compares Class 1 without Ras vs Class 3 with Ras mutations; C. Model III examines additional Ras mutation status within Class 3. P-values represent significance of violation of proportional hazards assumptions.
Year:
2025
Survival analysis of BRAF -mutant colorectal cancer classes: multivariate and univariate mixed-effects Cox proportional hazards models. Model I compares BRAF classes across all patients irrespective of additional Ras mutation; model II compares class 1 without Ras vs. class 3 with Ras mutations; model III examines additional Ras mutation status within class 3. All models include study as a random effect. Both univariate and multivariate analyses were performed on identical patient cohorts per model to ensure direct comparability.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (62)
Patricia Roxburgh
University of Glasgow
Rebecca C. Fitzgerald
Head of Academic Department
University of Cambridge
Claire Palles
Associate Professor
University of Birmingham
Enric Domingo
University of Oxford
Ines Gockel
University Hospital Leipzig
Xiaoyu Wang
University of Florida
Johannes Schumacher
Philipps-Universität Marburg
Nicholas West
University of Leeds School of Medicine
Philip Quirke
Yorkshire Cancer Research Centenary Professor of Pathology
University of Leeds
Wong-Ho Chow
Professor
The University of Texas MD Anderson Cancer Center
Richard Houlston
Professor
Institute of Cancer Research Sutton
Susanna Larsson
Professor at Karolinska Institutet
Karolinska Institutet
Ignacio Soriano
University of Oxford
Axel Hillmer
Assoc. Prof
University Hospital Bonn
Puya Gharahkhani
Team Head, Associate Professor
QIMR Berghofer Medical Research Institute
Markus Nöthen
Professor, Director
University Hospital Bonn
Philip Law
Institute of Cancer Research
Ulrike Peters
Fred Hutchinson Cancer Research Center
Graeme I Murray
-
Thomas Schmidt
Professor of Surgical Oncology / Chief Senior Consultant
Universitätsklinikum Bonn
Sharon B Love
Methodology Lead of Trial Conduct Research
University College London
Thomas Vaughan
Professor
University of Washington
Ju-Sheng Zheng
Principal Investigator
Westlake University
Lesley Anderson
University of Aberdeen
Philip Dunne
Group Leader
Cancer Research UK Beatson Institute
Keisuke Kataoka
Chief
National Cancer Center Research Institute
John de Caestecker
Honorary Professor
University of Leicester
Hans Prenen
Antwerp University Hospital
Carlo Maj
Head of Bioinformatics | Research Group Leader – Genetic Epidemiology
University of Marburg
Prasad Iyer
Professor of Medicine and Chair
Mayo Clinic Arizona
Quinn Ostrom
Assistant Professor
Duke University School of Medicine
Carlos Caldas
Professor
Hebrew University of Jerusalem
Viktor Koelzer
Medical Co-Director, Professor of Experimental Pathology
University of Zurich
Jesper Lagergren
Professor and Chair of Upper Gastrointestinal Cancer and Honorary Consultant Surgeon
King’s College London
David Whiteman
Deputy Director
QIMR Berghofer Medical Research Institute
Beatrice Melin
Professor
Umea University
Thomas Rösch
Chief of department, Prof. Dr
-
Stuart MacGregor
Professor
QIMR Berghofer Medical Research Institute
Yasunori Kogure
Senior Researcher
National Cancer Center Research Institute
Dominik Heider
Diretor
University of Münster
Anna H. Wu
Professor
University of Southern California
Manuel Salto-Tellez
Lead
Institute of Cancer Research
Leslie Samuel
University of Aberdeen
Timothy Stanley Maughan
Chair
University of Oxford
Lijuan Wang
University of Cambridge
Matthias Reeh
University Medical Center Hamburg-Eppendorf
Simon Bach
Professor of Colorectal Surgery
University of Birmingham
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Marino Venerito
-
Paul Moayyedi
Audrey Campbell Chair of Ulcerative Colitis Research
McMaster University
Francesca M. Buffa
Full Professor, Computing Sciences, AI in Health and Life Sciences
Bocconi University
Melissa Bondy
Professor/Department Chair
Stanford University
Yukinori Okada
University of Tokyo
Janusz Jankowski
Professor
University College London
Joanne Edwards
Professor
University of Glasgow
Shuai Yuan
Karolinska Institutet
Geoffrey Liu
The M. Qasim Choksi Chair in Lung Cancer Translational Research
University of Toronto
Malcolm Dunlop
Professor
University of Edinburgh
David Sebag-Montefiore
Professor of Clinical Oncology and Health Research
University of Leeds
Kathryn Pennel
Research Associate
University of Glasgow
Yuki Saito
National Cancer Center Research Institute
David Kerr
Professor of Cancer Medicine
University of Oxford
Make your next move.
Prepare your application
Review drafts before you send them.